MindLab is a biopharmaceutical company focused on developing and commercializing novel therapeutic products for the treatment of pain management disorders that address the prevalent issues of addiction, tolerance, side effects, durability, and adherence. Our mission is to ensure that no one suffers from pain without adequate treatment. MODERN PAIN MEDICATION IS RISKY: WE OFFER A SAFER ALTERNATIVE MLB-001 is a novel opioid analgesic which addresses the issues of drug craving and liking by attenuating the release of dopamine and controlling pain at significantly lower doses by potentiating its analgesic effect. MLB-001 has exceeded expectations in proof-of-concept testing. The activity of MLB-001 lasted 300% longer than morphine following BID administration. Please visit mindlabpharma.com to learn more about our groundbreaking research. The Mindlab team includes world-class specialists and researchers, and we have IP patent protection in the United States, Europe, Japan, and China.